Showing results (121-130 of 430) with videos related to
Sort By:
Pageof 43
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|December 2, 2006
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic studyJens Jakob Thune, Lars Køber, Marc A Pfeffer, et al.Clinical Journal of the American Society of Nephrology : CJASN|October 13, 2009
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndromeLisa M Mielniczuk, Marc A Pfeffer, Eldrin F Lewis, et al.Plos One|September 19, 2019
Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trialRaymond Y Kwong, Bobak Heydari, Yin Ge, et al.European Journal of Heart Failure|November 2, 2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarctionJens Jakob Thune, James E Signorovitch, Lars Kober, et al.The New England Journal of Medicine|November 9, 2004
Angiotensin-converting-enzyme inhibition in stable coronary artery diseaseEugene Braunwald, Michael J Domanski, Sarah E Fowler, et al.The American Journal of Cardiology|July 28, 2004
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathyDavid Aguilar, Samuel Z Goldhaber, Daniel J Gans, et al.Lancet (London, England)|May 27, 2008
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trialJean-Claude Tardif, John J V McMurray, Eric Klug, et al.JACC. Heart Failure|November 15, 2020
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HFKarola S Jering, Faiez Zannad, Brian Claggett, et al.Pageof 43